Berger, Julia M.
Gansterer, Margaretha
Trutschnig, Wolfgang
Bathke, Arne C.
Strassl, Robert
Lamm, Wolfgang
Raderer, Markus
Preusser, Matthias
Berghoff, Anna S.
Funding for this research was provided by:
Medical University of Vienna
Article History
Received: 16 March 2021
Accepted: 21 July 2021
First Online: 19 August 2021
Conflict of interest
: M. Preusser has received fees for lectures, consultation or advisory board participation from the following for-profit companies: Bayer, Bristol-Myers Squibb, Novartis, Gerson Lehrman Group (GLG), CMC Contrast, GlaxoSmithKline, Mundipharma, Roche, BMJ Journals, MedMedia, Astra Zeneca, AbbVie, Lilly, Medahead, Daiichi Sankyo, Sanofi, Merck Sharp & Dome, Tocagen. The following for-profit companies have supported clinical trials and contracted research conducted by MP with payments made to the institution: Böhringer-Ingelheim, Bristol-Myers Squibb, Roche, Daiichi Sankyo, Merck Sharp & Dome, Novocure, GlaxoSmithKline, AbbVie. A.S. Berghoff has received research support from Daiichi Sankyo (≤ 10000 €), Roche (> 10000 €) and fees for lectures, consultation or advisory board participation from Roche Bristol-Meyers Squibb, Merck, Daiichi Sankyo (all < 5000 €) as well as travel support from Roche, Amgen and AbbVie. M. Raderer has received fees for lectures or advisory boards by Novartis, Roche, Ipsen, Celgene, Eli Lilly and Eisai. J.M. Berger, M. Gansterer, W. Trutschnig, A.C. Bathke, R. Strassl and W. Lamm declare that they have no competing interests.